SNDXSyndax Pharmaceuticals Inc
Earnings Recap
• Reported GAAP EPS of -$0.78 up 29.09% YoY • Reported revenue of $68.73M up 794.90% YoY • Syndax Pharmaceuticals expects to continue incurring significant losses for the near future as it advances commercialization and development activities, though existing cash and investments are projected to fund operations for at least the next 12 months.
Bullish
Syndax Pharmaceuticals benefits from two first-in-class FDA-approved medicines, a robust pipeline expansion for new indications, and a $350M upfront payment from a royalty agreement.
Bearish
Syndax Pharmaceuticals incurred a $285.4M net loss in 2025, faces significant competition from established therapies, and risks its intellectual property protection, which could impair future revenue generation.